Working… Menu
Trial record 4 of 141 for:    appendix cancer

LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03287947
Recruitment Status : Recruiting
First Posted : September 19, 2017
Last Update Posted : October 1, 2019
Boehringer Ingelheim
Information provided by (Responsible Party):
Jimmy Hwang, Atrium Health

Brief Summary:
The purpose of this trial is to evaluate the disease control rate of nintedanib in subjects with metastatic appendiceal cancer for whom initial fluoropyrimidine-based chemotherapy has failed. Based on previous studies, the anticancer activityof nintedanib in lung and ovarian cancer trials, along with the similarities between appendiceal and colorectal cancer and potentially ovarian cancer, warrant additional investigation for the optimal treatment of metastatic appendiceal carcinomas.

Condition or disease Intervention/treatment Phase
Appendix Cancer Drug: nintedanib Phase 2

Detailed Description:
The primary study objective is to evaluate the disease control rate. The secondary study objectives are to evaluate safety and toxicity, objective response rate, overall and 6-month progression free survival, and overall survival. Exploratory study objectives include evaluation of serum and ascites VEGF, hypertension, and paracentesis frequency in subjects with ascites at study entry.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 39 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Single arm phase 2 study.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma
Actual Study Start Date : November 10, 2017
Estimated Primary Completion Date : September 1, 2021
Estimated Study Completion Date : March 1, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: A
Drug: nintedanib
Oral nintendanib, taken twice daily

Primary Outcome Measures :
  1. Disease Control Rate [ Time Frame: up to 48 months ]
    Sum of Overall Response Rate and Stable Disease by RECIST

Secondary Outcome Measures :
  1. Safety of Nintedanib, as measured by toxicity [ Time Frame: up to 48 months ]
    Assessed by NCI CTC version 4

  2. Overall Survival [ Time Frame: up to 48 months ]
    Survival from Enrollment onto Study

  3. Progression Free Survival [ Time Frame: up to 48 months ]
    Time from Enrollment to the development of progressive disease, or death

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Subjects must meet all of the following criteria:

  1. Age at least 18 years old
  2. Histologically confirmed appendiceal carcinoma stage IV
  3. Failure of initial fluoropyrimidine -based chemotherapy. Failure is defined as progression on or within 6 months of last day of therapy or intolerance of initial fluroropyrimdine-based chemotherapy.
  4. Life expectancy at least 3 months
  5. ECOG performance status score 0-2
  6. Presence of measurable and/or evaluable, non-measurable disease according to RECIST 1.1 criteria
  7. Written informed consent signed and dated by subject or Legally Authorized Representative (LAR) prior to admission to the study in accordance with ICH-GCP guidelines and to the local legislation.

Exclusion Criteria

Subjects must not meet any of the following criteria.

  1. Prior treatment with nintedanib or any other VEGFR inhibitor
  2. Known hypersensitivity to peanut or soya or to contrast media. History of hypersensitivity to contrast media is allowed if the subject is able to tolerate contrast media with pre-medication.
  3. Chemo-, hormone-, radio-(except for brain and extremities) or immunotherapy, or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks prior to treatment with the trial drug.
  4. Radiotherapy to any target lesion within the past 3 months prior to baseline imaging when that target lesion is the only target lesion identified on baseline imaging, unless it has subsequently grown.
  5. Persistence of clinically relevant therapy related toxicity from previous chemo and/or radiotherapy as determined by the investigator.
  6. Active brain metastases (e.g. stable for <4 weeks, no adequate previous treatment with radiotherapy, symptomatic, requiring treatment with anti-convulsants; dexamethasone therapy will be allowed if administered as stable dose for at least one month) or leptomeningeal disease.
  7. Radiographic evidence of cavitary or necrotic tumors.
  8. Tumors with radiographic evidence (CT or MRI) of local invasion of major blood vessels.
  9. Anti-neoplastic treatment for appendiceal cancer, with other investigational drugs or treatment in another clinical trial within 30 days before start of study treatment.
  10. Therapeutic anticoagulation with drugs requiring INR monitoring (except low-dose heparin and/or heparin flush as needed for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except for low-dose therapy with acetylsalicylic acid less than or equal to 325mg per day).
  11. Major injuries and/or surgery within the past 4 weeks prior to start of study treatment, incomplete wound healing or planned surgery during the on-treatment study period.
  12. History of clinically significant hemorrhagic or thromboembolic event in the past 6 months prior to consent.
  13. Known inherited predisposition to bleeding or thrombosis.
  14. Significant cardiovascular diseases (i.e. uncontrolled hypertension, unstable angina, history of infarction, congestive heart failure > NYHA II, serious cardiac arrhythmia, pericardial effusion) within the past 12 months prior to start of study treatment.
  15. Proteinuria CTCAE grade 2 or greater.
  16. Creatinine > 1.5x ULN or GFR < 45 ml/min.
  17. Hepatic function: total bilirubin above normal limits; ALT or AST > 1.5x ULN in subjects without liver metastasis. For subjects with liver metastasis: total bilirubin above normal limits; ALT or AST > 2.5x ULN.
  18. Coagulation parameters: International normalised ratio (INR) > 2x ULN, prothrombin time (PT) and partial thromboplastin time (PTT) > or equal to 1.5x ULN.
  19. Absolute neutrophil count (ANC) < 1500/ml, platelets < 100000/ml, Hemoglobin < 9.0 g/dl.
  20. Other malignancies at the time of signing the informed consent other than basal cell skin cancer or carcinoma in situ of the cervix.
  21. Active serious infections if requiring systemic antibiotic or antimicrobial therapy.
  22. Active or chronic hepatitis C and/or B infection.
  23. Gastrointestinal disorders (like chronic diarrhea) or abnormalities that would interfere with absorption of the study drug. Subjects with this disorder may be allowed if able to tolerate anti-diarrheal medications like loperamide.
  24. Serious illness or concomitant non-oncological disease such as neurologic, psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or laboratory abnormality that may increase the risk associated with study participation or study drug administration and in the judgment of the investigator would make the subject inappropriate for entry into the study.
  25. Sexually active women of child-bearing potential and men who are sexually active with women of child-bearing potential and unwilling to use at least 2 medically acceptable methods of contraception (e.g. such as implants, injectables, combined oral contraceptives, some intrauterine devices or vasectomized partner for participating females, condoms for participating males) during the trial and for at least three months after end of active therapy. Female subjects will be considered of child-bearing potential unless surgically sterilized by hysterectomy or bilateral tubal/salpingectomy, or post-menopausal for at least 2 years.
  26. Pregnancy or breast feeding; female participants of child-bearing potential must have a negative pregnancy test (B-HCG test in urine or serum) before commencing study treatment.

aa. Psychological, familial, sociological, or geographical factors potentially hampering compliance with the study protocol and follow-up schedule per the investigator.

bb. Alcohol or drug abuse which in the determination of the investigator would interfere with trial participation.

cc. Significant weight loss (> 10% of baseline weight) within past 2 months prior to consenting for the trial. Removal of ascites should not be calculated as weight loss.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03287947

Layout table for location contacts
Contact: Nathan Thompson, RN 980-442-9432

Layout table for location information
United States, North Carolina
Levine Cancer Institute Recruiting
Charlotte, North Carolina, United States, 28204
Contact: Nathan Thompson    980-487-3241   
Sponsors and Collaborators
Jimmy Hwang
Boehringer Ingelheim
Layout table for investigator information
Principal Investigator: Jimmy J Hwang, MD Atrium Health

Layout table for additonal information
Responsible Party: Jimmy Hwang, Chief, GI Medical Oncology, Levine Cancer Institute, Atrium Health Identifier: NCT03287947     History of Changes
Other Study ID Numbers: LCI-GI-APX-NIN-001
00021617 ( Other Identifier: Advarra IRB )
First Posted: September 19, 2017    Key Record Dates
Last Update Posted: October 1, 2019
Last Verified: September 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Appendiceal Neoplasms
Cecal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Cecal Diseases
Intestinal Diseases
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action